Deferred Tax Assets, Valuation Allowance of Sigyn Therapeutics, Inc. from 31 Dec 2014 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Sigyn Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2014 to 31 Dec 2024.
  • Sigyn Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $3,958,470, a 31% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Sigyn Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $3,958,470 +$934,712 +31% 31 Dec 2024 10-K 15 Apr 2025 2024 FY
Q4 2023 $3,023,758 +$1,349,227 +81% 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q4 2022 $1,674,531 +$601,004 +56% 31 Dec 2022 10-K 20 Feb 2024 2023 FY
Q4 2021 $1,073,527 +$720,615 +204% 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q4 2020 $352,912 +$352,478 31 Dec 2020 10-K 21 Mar 2022 2021 FY
Q4 2019 $434* -$3,451,747 31 Dec 2019 10-K 06 Apr 2021 2020 FY
Q4 2018 $3,452,181 +$786,346 +29% 31 Dec 2018 10-K 30 Mar 2020 2019 FY
Q4 2017 $2,665,835 31 Dec 2017 10-K 01 Apr 2019 2018 FY
Q4 2015 $1,319,919 +$1,071,859 +432% 31 Dec 2015 10-K 30 Mar 2016 2015 FY
Q4 2014 $248,060 31 Dec 2014 10-K 30 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.